Downloads
Abstract
Background: Outcome of the BRIGHTNESS study, presented at ESMO 2021, demonstrated the efficacy of adding Carboplatin to the Neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients. The regimen of Paclitaxel - Carboplatin + Doxorubicin-Cyclophosphamide (TC-AC) chemotherapy has been applied in Neoadjuvant chemotherapy treatment for TNBC patients at K Hospital and has shown promising clinical practice results.
Methods: Cross-sectional study on 31 triple-negative breast cancer (TNBC) patients underwent treatment with Neoadjuvant chemotherapy regimen of TC-AC at K Hospital from January 2021 to January 2024. The primary endpoint was the total complete pathological response (ptCR). The secondary endpoint was safety of TC-AC regimen.
Results: The median age was 44,2 (range 30 - 71 years). Of these 31 patients, 4 (12.8%) were at stage II, 27 (87,2%) were at stage III, 3 (9,7%) patients carried mutated BRCA1 and/or BRCA2 genes, 1 (3,2%) patient carried mutated PALB2. Total pathological complete response (tpCR) was achieved in 14 (46,7%) of the evaluated patients. Grade 3 or 4 hematological toxicity occurred in 8 (25,8 %) patients with anemia. Grade 3 or 4 non-hematological toxicities 12 (38,7%) patients include hepatotoxicity, fatigue, and diarrhea.
Conclusions: These findings support the TC-AC neoadjuvant chemotherapy for early-stage TNBC with improvement in tpCR and manageable safety profile.
References
Geyer CE, Sikov WM, Huober J, et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann Oncol.2022;33(4):384-394.
GLOBOCAN. New global cancer data. 2020.
GLOBOCAN 2020: New Global Cancer Data | UICC. Available at https://www.uicc.org/news/globocan-2020-global-cancer-data. Accessed June 28, 2024.
de Ruijter TC, Veeck J, de Hoon JPJ, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 2011;137(2):183-192.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27-39.
Shepherd JH, Ballman K, Polley MYC, et al. CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. J Clin Oncol. 2022;40(12):1323-1334.
De Ruijter T.C, Veeck J, de Hoon J.P.J, et al. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 2011; 137(2):183–192.
Rastogi P, Anderson SJ, Bear HD, et al. Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. JCO.2008;26(5):778-785.
Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine. 2020;382(9):810-821.
Geyer CE, Sikov WM, Huober J, et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals of Oncology. 2022;33(4):384-394.
| Published | 23-12-2024 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 16 No. 6 (2024) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.16.6.13 | |
| Keywords | Ung thư vú bộ ba âm tính, điều trị bổ trợ trước ung thư vú, điều trị ung thư vú Triple-negative breast cancer, breast cancer treatment, neo-adjuvant chemotherapy |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2024 Journal of Clinical Medicine Hue Central Hospital